Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VRB-104
- Development stage
- Preclinical
- Lead developer
- Verdiva Bio
- Modality
- Peptides
01
Overview
VRB-104 is a peptide-based therapeutic candidate developed by Verdiva Bio for the treatment of cardiometabolic disorders. As of early 2024, the drug is in the IND-enabling phase of development. While the specific molecular target and mechanism of action have not been publicly disclosed by the company, VRB-104 is part of a pipeline focused on metabolic health that includes GLP-1 and amylin receptor agonists. The drug is being engineered to address the complex pathophysiology of cardiometabolic diseases, leveraging Verdiva Bio's expertise in peptide drug discovery and development.
02
Targets
Beyond the preview
Go deeper on VRB-104.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VRB-104.